Tooth Regeneration Tideglusib Powder Tideglusib

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: QS-Tideglusib
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Product Name: Tideglusib
• Name: Tideglusib Powder
• Appearance: White Powder
• Colour: White
• Grade: Pharmaceutical Grade
• Assay: >99%
• Application: API
• Specific: COA
• Test Method: HPLC
• CAS: 865854-05-3
• Mf: C19h14n2o2s
• MW: 334.39166
• Density: 1.393
• Melting Point: 148-150c
• Boiling Point: 760 Mmhg
• Transport Package: Negotiable
• Specification: >99%
• Trademark: QS-Tideglusib
• Origin: Xian
• Production Capacity: 10000kg/Month

Product Description

Tooth Regeneration Tideglusib Powder Tideglusib

Product Description

Product Details

Product Name	Tideglusib
Appearance	White Powder
Assay	99%
MW	334.39166
MF	C19H14N2O2S

Tideglusib is mainly used for the treatment of Alzheimer's disease and progressive supranuclear palsy. Due to pathological changes such as excessive phosphorylation of tau protein and deposition of amyloid protein in the brains of Alzheimer's disease patients, and the association between progressive supranuclear paralysis and neurodegeneration, Tideglusib may have a positive effect on the treatment of these diseases through its pharmacological effects.

Application&Function

Pharmacological action
Reduce tau protein phosphorylation levels
In human neuroblastoma cells and primary neurons of mice, Tideglusib irreversibly inhibits GSK-3, leading to a decrease in tau protein phosphorylation levels and preventing cell apoptosis. In APP/tau transgenic mice, oral administration of 200 mg/kg Tideglusib can also reduce tau protein phosphorylation levels.
Inhibition of glial cell activation
Tideglusib (2.5 μ M) inhibits glutamate induced activation of glial cells, as evidenced by decreased expression levels of TNF - α and COX-2 in rat primary astrocytes or microglia.
Protecting nerve cells
Anti excitotoxicity: Tideglusib (2.5 μ M) has an effective protective effect on cortical neurons, which can protect nerves from glutamate induced excitotoxicity. Evidence shows that the number of Annexin-V positive cells in rat primary astrocytes or microglia is significantly reduced.
Reducing inflammatory response and protecting hippocampus: Injecting 50mg/kg Tideglusib into the hippocampus of adult male Wistar rats can significantly reduce the inflammatory response induced by kainic acid and have a protective effect on the damaged area of the hippocampus.
Reducing amyloid deposition: In APP/tau transgenic mice, Tideglusib (200mg/kg, orally administered) can reduce amyloid deposition and plaque related astrocyte proliferation, protect neurons in the entorhinal cortex and hippocampal CA1 region from death, and prevent memory loss.
Other functions
Tideglusib can also protect neural stem cells from the effects of excessive activation of NMDA receptors, reduce the progression of brain atrophy in patients with progressive supranuclear palsy in randomized trials, and prevent inflammation and neurodegeneration under excitotoxic conditions.

Specification